Look closer at what we know.

Rhythm & stroke

Annualized efficacy events: 0.78% with apixaban versus 1.24% with aspirin; major bleeding increased.

Rhythm & stroke

No significant reduction in the primary efficacy composite; more death or major bleeding in the safety composite.

Rhythm & stroke

No significant reduction in recurrent stroke with apixaban.

Rhythm & stroke

No benefit on the primary composite endpoint.

Rhythm & stroke

Noninferiority for the efficacy composite and superiority for non-procedural bleeding.

Stress & perception

Mental-stress-induced myocardial ischemia was associated with cardiovascular events.

Stress & perception

Physical triggers were more common than emotional triggers; some patients had no evident trigger. Serious complications occur.

Stress & perception

Increasing heart rate influenced behavior, with posterior insular cortex implicated.

Pressure & cognition

Mild cognitive impairment was reduced; probable dementia was not statistically conclusive.

Pressure & cognition

Risk ratio 0.85; 95% confidence interval 0.76–0.95. The intervention included supervised medication management and care support.

Heart failure

Functional status, exercise capacity, and quality-of-life benefits persisted; the primary hard-outcome endpoint was neutral.

Heart failure

The primary endpoint did not improve.

Sleep & recovery

No major cardiovascular-event prevention benefit in the intention-to-treat analysis.

Sleep & recovery

Heart injury influenced brain immune signaling and sleep, suggesting a role in recovery.

Dysautonomia

A promising investigational signal for a specific population.

Dysautonomia

NPY2R-expressing vagal sensory neurons were implicated in fainting mechanisms.

Dysautonomia

New research identifies specific sensory pathways in circulatory defense.

Rhythm & stroke

AF burden was lower with active treatment in this small proof-of-concept study.

Rhythm & stroke

Prospective observational evidence supports investigation in an acute specialist setting.

Rehabilitation

The pivotal trial supports paired stimulation in a defined rehabilitation population.

Neuroimmune

A specific heart–brain neuroimmune circuit was identified and perturbed.

Sleep & recovery

CPAP reduced blood pressure relative to the comparator groups during the trial.